The Sensulin technology — developed by Ananth Annapragada, a researcher at Texas Children's Hospital and Baylor College of Medicine, and Sensulin co-founder — may mimic the healthy human pancreas, Moradi said. It could eliminate the need for separate basal and prandial insulin injections, he said, and profoundly improve the standard of care for type 1 and type 2 diabetes patients.
“We intend to disrupt the $17 billion global insulin market, make glucometers and multiple injections per day obsolete, and give those with diabetes a chance at a normal life,” said Moradi, who has diabetes on both sides of his family. He anticipates clinical trials of Sensulin to begin in 24 to 36 months.
At the Texas Life Science Venture Forum last month in Houston, Sensulin was awarded the Michael E. DeBakey Life Science Award, presented to the life science company with highest potential to commercialize an important product and chosen by a panel of venture capital firms and representatives from leading pharmaceutical companies. Sensulin also brought home the Rice Alliance Most Promising Life Science Technology Award.
Diabetes by the numbers
Worldwide, 350 million people have diabetes. The number is predicted to be 550 million by 2030.